Achieve life sciences announces proposed underwritten public offering

Seattle, wa and vancouver, bc / accesswire / may 24, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. in addition, achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
ACHV Ratings Summary
ACHV Quant Ranking